Do Weight-Loss Medications Help Arthritis Pain?

This has become one of the most common questions in my office. A patient with an arthritic hip or knee is on a weight-loss medication, or is thinking about starting one, and wants to know whether it is going to help the joint.

It is a fair question, and there is now actual trial data to talk about rather than speculation. But that data varies enormously in quality — some of it is a randomized trial published in a major medical journal, and some of it is a press release from the company that makes the drug. Those get quoted side by side online as though they carry equal weight. They do not, and this page keeps them apart.

The short answer

Losing weight reduces the load on an arthritic hip or knee, and in the best available trial that translated into more pain improvement than placebo. What none of this shows is that arthritis reverses.

Both halves of that sentence matter. The first half is why I take the question seriously instead of dismissing it. The second half is why I am careful about how these results are presented to patients.

What these medications actually are

The medications people are asking about belong to a class usually described as GLP-1 medications. Semaglutide is sold as Ozempic and Wegovy. Tirzepatide is sold as Mounjaro and Zepbound. They were developed for type 2 diabetes and obesity, and they produce weight loss that is substantially larger than what was achievable with earlier medications.

None of them were developed as arthritis treatments. That is worth stating at the outset, because the interest in them for joint pain came after the fact — from the observation that people losing a great deal of weight often reported that their knees felt better.

Why weight matters to a worn joint

The mechanical part of this is not controversial and does not depend on any drug trial.

A hip and a knee carry your body weight every time you take a step, and the forces across the joint during walking are considerably higher than body weight alone. Research on knee loading has estimated that each pound of body weight translates to roughly four pounds of additional force across the knee during normal walking. Whatever the exact multiplier in any individual, the direction is clear: less weight means less load on a joint surface that has already lost its cushioning.

There is a second effect that gets less attention. Fat tissue is metabolically active and contributes to systemic inflammation, and osteoarthritis is not a purely mechanical disease. So weight loss may act on an arthritic joint through more than one route.

This is the same reasoning behind the weight discussion in knee osteoarthritis and hip osteoarthritis generally — it long predates these medications.

What the semaglutide trial showed

This is the strongest piece of evidence in this area, and it is the one worth knowing in some detail.

A randomized trial published in the New England Journal of Medicine in 2024 enrolled 407 adults who had obesity together with a diagnosis of moderate knee osteoarthritis and moderately severe knee pain. Participants received either semaglutide or placebo for 68 weeks, alongside lifestyle measures.

I include the placebo numbers deliberately, because most summaries of this trial do not. A 27.5-point improvement in the placebo group is substantial. Knee pain in a trial setting improves for a lot of reasons — attention, activity changes, expectation, and the natural fluctuation of arthritis symptoms.

That does not undermine the result. Semaglutide clearly outperformed placebo, and this is a well-conducted, peer-reviewed, randomized trial — which puts it in a different category from almost everything else being discussed in this space. But it does mean that quoting the semaglutide number on its own overstates what the medication contributed.

Retatrutide — what is in the pipeline

Retatrutide is the drug generating the most attention right now, and it requires more caution, not less.

It is an investigational medication acting on three receptors rather than one, and its manufacturer has reported Phase 3 results in adults with obesity and knee osteoarthritis — large weight loss and a large reduction in knee pain scores.

I go through the reported numbers, the placebo comparison and what approval would actually mean in retatrutide and knee arthritis. The short version is that there is a real difference between this is worth following and this works, and right now it is firmly the first one.

What none of this proves

Every trial discussed above measured pain, function and body weight. None of them demonstrated structural change in the joint.

This distinction gets lost constantly, and it matters more than almost anything else on this page. Cartilage that has worn away does not come back because the load across it decreased. A knee that is bone-on-bone before losing 60 pounds is still bone-on-bone after. What can change is how much that joint hurts and how much you can do — which is a real and worthwhile outcome, and a completely different claim.

If a page tells you that a weight-loss medication regenerates cartilage or reverses arthritis, it has gone beyond the evidence.

What weight loss cannot fix

There is a category of joint problem where weight loss simply does not address what is wrong. It is worth knowing which side of that line you are on before deciding that a medication is the answer.

Mechanical symptoms — a knee that locks or catches, a joint that gives way, a leg that has visibly bowed or angled, a hip that has lost the rotation needed to put a sock on — reflect a structural problem. So does pain that wakes you every night, and pain that persists at rest rather than with activity. Those are not load problems. Reducing load helps many things; it does not straighten a deformity or stabilize a joint.

The other reason this matters is that not all hip and knee pain is arthritis in the first place. Bursitis, a meniscus tear, a labral tear, referred pain from the spine, avascular necrosis and inflammatory arthritis can all produce symptoms that feel similar and need entirely different treatment.

If your BMI is over 40

This is where my own position is most specific, and it is not really about arthritis pain at all.

Above a BMI of 40, I recommend patients have a conversation with their primary care physician about weight-loss options, including these medications. That recommendation is based on the surgical infection and complication literature, not on how anybody looks.

The numbers behind it are worth seeing plainly. A BMI of 35 to 39.9 is associated with roughly twice the risk of deep infection after joint replacement, and a BMI over 40 with roughly four times the risk. In absolute terms that is a shift from around 1% to around 4% over fifteen years. Meaningful — and also not the near-certainty patients sometimes fear.

I go through this in detail, including where the thresholds sit and what happens between 40 and 50, in BMI and joint replacement. If you have diabetes as well, the interaction between weight, A1c and surgical risk is covered in diabetes, A1c and joint replacement.

One practical point that applies to anyone already taking one of these medications and heading toward surgery: they need to be stopped before the operation for anesthesia safety and restarted afterward for wound healing. The specific timing I use is in the BMI article above. Tell us what you are taking so that gets planned properly.

Before you treat joint pain, find out what it is

If you are reading this because your hip or knee hurts, the most useful thing you can do is not choosing between medications. It is finding out what is actually causing the pain.

An examination and a weight-bearing X-ray answer most of it: whether this is arthritis, how much cartilage is left, whether the alignment has changed, and whether the problem is even in the joint you think it is. That takes one visit, and it determines everything that follows — including whether weight loss is likely to make a real difference to your symptoms or to be beside the point.

There is also a great deal that can be done for an arthritic hip or knee short of surgery, and it is worth knowing what those options are before assuming the choice is between a medication and an operation. Those are laid out in non-surgical treatment for hip and knee arthritis.

What I am not saying

I want to be precise about the limits of this page, because this is an area where enthusiasm outruns evidence quickly.

I am not saying these medications treat arthritis. I am not saying they should be started for joint pain. I am not saying the retatrutide results are established — they are manufacturer-reported and that drug is not approved. And I am not prescribing or managing these medications; that belongs with your primary care physician.

What I am saying is narrower. Weight loss reduces the load on a worn hip or knee. In one well-conducted randomized trial, a medication that produces substantial weight loss improved knee arthritis pain more than placebo did. More data is coming, some of it specifically in knee osteoarthritis, and it deserves to be read carefully rather than through a headline.

And regardless of which medication you are or are not taking: hip and knee pain that persists deserves a diagnosis. That is the part I can help with.